Explore Jobs
Find Specific Jobs
Explore Careers
Explore Professions
Best Companies
Explore Companies
Insmed's peak revenue was $245.4M in 2022. The peak quarterly revenue was $79.1M in 2023(q3).
Insmed's revenue increased from $60.0k in 2000 to $245.4M currently. That's a 408,830.0% change in annual revenue.
Fiscal Year / Year | Insmed Revenue |
---|---|
2009 | $10.4M |
2010 | $6.9M |
2011 | $4.4M |
2013 | $11.5M |
2018 | $9.8M |
2019 | $136.5M |
2020 | $164.4M |
2021 | $188.5M |
2022 | $245.4M |
How accurately did Insmed's revenue projections match actual performance?
Insmed saw the greatest revenue growth in 2019, when revenue increased by 1,287.56%.
Insmed had the lowest revenue growth in 2003, when revenue changed by -92.33%.
Year | Insmed Growth |
---|---|
2009 | -11%↓ |
2010 | -33%↓ |
2011 | -36%↓ |
2013 | 160%↑ |
2018 | -14%↓ |
2019 | 1288%↑ |
2020 | 20%↑ |
2021 | 15%↑ |
2022 | 30%↑ |
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2009 | $2.4M | $3.0M | $2.5M | $2.5M |
2010 | $1.9M | $1.9M | $1.8M | $1.3M |
2011 | $1.6M | $978,000 | $435,000 | $1.4M |
2013 | - | $11.5M | - | - |
2018 | - | - | - | $9.8M |
2019 | $21.9M | $30.0M | $38.9M | $45.7M |
2020 | $36.9M | $42.5M | $43.6M | $41.4M |
2021 | $40.2M | $45.4M | $46.8M | $56.1M |
2022 | $53.1M | $65.2M | $67.7M | $59.3M |
2023 | $65.2M | $77.2M | $79.1M | - |
Do you work at Insmed?
Did Insmed meet its revenue projections?
CEO | William H. Lewis J.d |
Industry | Pharmaceuticals, Biotechnology & Life Sciences |
Company Type | Public |
Employees Number | 373 |
Date Founded | 1988 |
Headquarters | Bridgewater, New Jersey |
Number of Locations | 1 |
Revenue | $245.4M |
Net Income | -$481,534,000 |
Gross Proft | $190.2M (2022) |
EBITDA | ($448.7M) (2022) |
PE Ratio | -3.57 |
Tax Rate | -0.0% |
Market Capitalization | $1.7B |
Total Assets | $1,656,435,000 |
Ticker | INSM |
Insmed received early financing of $32.8M on 2005-03-15.
Series | Round Size | Date |
---|---|---|
Post Ipo Debt | $32.8M | 03/2005 |
Post Ipo Equity | $377.7M | 09/2017 |
Post Ipo Debt | $435.8M | 01/2018 |
Post Ipo Equity | $235.5M | 05/2019 |
Post Ipo Equity | $25.6M | 06/2019 |
Post Ipo Equity | $259.4M | 05/2020 |
Investors | Security Type |
---|---|
Forbion Capital Partners | Post-IPO Equity - Insmed |
Company Name | Average Salary | Revenue | Employee Size | Job Openings |
---|---|---|---|---|
Genentech | $97,473 | $166.9M | 13,638 | 459 |
PDL BioPharma | $48,962 | $30.7M | 75 | - |
BioMarin | $87,259 | $2.1B | 2,581 | 115 |
Novartis Consumer Health Inc | $49,843 | $6.4M | 50 | - |
RQM | $73,114 | $15.4M | 405 | 22 |
SI-BONE | $74,689 | $106.4M | 183 | 19 |
Onyx Pharmaceuticals | $95,378 | $362.2M | 500 | - |
Histogen | $50,606 | $17.8M | 19 | - |
Kyphon | $71,077 | - | 3,000 | - |
Philips Healthcare | $85,358 | $6.8B | 24,000 | 138 |
Zippia gives an in-depth look into the details of Insmed, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Insmed. The employee data is based on information from people who have self-reported their past or current employments at Insmed. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Insmed. The data presented on this page does not represent the view of Insmed and its employees or that of Zippia.
Insmed may also be known as or be related to INSMED INC, Insmed, Insmed Incorporated and Insmed, Inc.